These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
204 related items for PubMed ID: 22614575
1. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Peuvrel L, Quéreux G, Brocard A, Saint-Jean M, Dréno B. Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575 [Abstract] [Full Text] [Related]
3. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE. Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578 [Abstract] [Full Text] [Related]
10. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Grgic T, Mis L, Hammond JM. Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421 [Abstract] [Full Text] [Related]
16. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial. N Engl J Med; 2007 May 31; 356(22):2271-81. PubMed ID: 17538086 [Abstract] [Full Text] [Related]
17. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]. Ravaud A, Bernhard JC, Gross-Goupil M, Digue L, Ferriere JM. Bull Cancer; 2010 May 31; 97():45-51. PubMed ID: 20418203 [Abstract] [Full Text] [Related]